

REMARKS

The present application is a divisional containing the non-elected claims of the parent application, claims 25-30, 47-50 and 67-70.

Formulas in the specification and claims have been amended to conform with changes made in the parent application. The groups BO, B'O, B''O have been replaced with B, B' and B''. It is believed that this change avoids possible confusion since the references to, for example, BO might suggest an additional oxygen is present when this is not the case. No new matter is involved as the correction is evident from, for example, the formula given for the Applicants' preferred compound. See Scheme 1A.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: 

Robert W. Hahl
Registration No. 33,893
Telephone: 703.905.2251
Fax: 703.905.2500

RWH/ml

1600 Tysons Boulevard
McLean, Virginia 22102
Phone: (703) 905-2118


Enclosures: Appendix

APPENDIX

Version with Markings to Show Changes Made

IN THE SPECIFICATION

Page 3, formula (i) has been changed as follows:





Page 3, the paragraph starting in line 26 has been changed as follows:

A, A'[,] A'', and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, linear or branched C₁-C₂₀ alkanoyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy; C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; and n, m, [and] p and v are independently integers from 0 to 3;



Page 4, the paragraph starting in line 3 has been changed as follows:

R'', R''' and R'''' [R''', R'''' and R'''''] are independently H, C₁-C₂₀ linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxycarbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, C₁-C₂₀ alkoxycarbonyl, OH, C₁-C₂₀ alkoxy, halo, or cyano.


Page 4, formula (II) has been changed as follows:




Page 5, formula (III) has been changed as follows:



Page 9, Scheme I has been replaced as follows:




Scheme I



IN THE CLAIMS:

25. (Amended) A compound of the formula II:



wherein stereocenters * are R or S;

dotted lines indicate[s] that a double bond may be present or absent, and the double bond geometry may be E or Z;


A, A', and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; and t, u, and w are independently integers from 0 to 3;

B and B' are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ alkanoyl, C₁-C₂₀ alkenoyl, C₁-C₂₀ alkenyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; C₆-C₂₀ aroyl, C₆-C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and x and y are independently integers from 0 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxycarbonyl, NH₂, CONH₂, C₁-

C_{20} acylamino, [C_1 – C_{20} alkoxycarbonyl,] OH, C_1 – C_{20} alkoxy, halo or cyano. $X=NH$, O, S, $S=O$, or SO_2 .

26. (Amended) A [pharmaceutically] pharmaceutical composition containing a blood glucose lowering effective amount of a compound of the formula II in a pharmaceutically acceptable carrier.



wherein stereocenters * are R or S;

dotted lines indicate[s] that a double bond may be present or absent, and the double bond geometry may be E or Z;


A , A' , and C are independently H, C_1 – C_{20} acylamino, C_1 – C_{20} acyloxy, C_1 – C_{20} alkoxycarbonyl, C_1 – C_{20} alkoxy, C_1 – C_{20} linear or branched alkylamino, C_1 – C_{20} alkylcarboxylamino, C_1 – C_{20} carbalkoxy; carboxyl, cyano, halo, hydroxy; and t , u , and w are independently integers from 0 to 3;

B and B' are independently H, C_1 – C_{20} acylamino, C_1 – C_{20} acyloxy; C_1 – C_{20} alkanoyl, C_1 – C_{20} alkenoyl, C_1 – C_{20} alkenyl, C_1 – C_{20} alkoxycarbonyl, C_1 – C_{20} linear or branched alkoxy, C_1 – C_{20} linear or branched alkylamino, C_1 – C_{20} alkylcarboxylamino, C_1 – C_{20} carbalkoxy; C_6 –

C₂₀ aroyl, C₆–C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and x and y are independently integers from 0 to 3;

R', R'', and R''' are independently H or C₁–C₂₀ linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C₁–C₂₀ alkoxy, carbonyl, NH₂, CONH₂, C₁–C₂₀ acylamino, [C₁–C₂₀ alkoxy, carbonyl,] OH, C₁–C₂₀ alkoxy, halo or cyano. X=NH, O, S, S=O, or SO₂.

27. (Amended) A method for lowering blood glucose in a subject comprising administering to said subject an effective blood glucose lowering amount of a composition of the formula II



wherein stereocenters * are R or S;



dotted lines indicate[s] that a double bond may be present or absent, and the double bond geometry may be E or Z;

A, A', and C are independently H, C₁–C₂₀ acylamino, C₁–C₂₀ acyloxy, C₁–C₂₀ alkoxy, C₁–C₂₀ linear or branched alkylamino, C₁–C₂₀ alkylcarboxylamino, C₁–C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; and t, u, and w are independently integers from 0 to 3;

B and B' are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ alkanoyl, C₁-C₂₀ alkenoyl, C₁-C₂₀ alkenyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; C₆-C₂₀ aroyl, C₆-C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and x and y are independently integers from 0 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxycarbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, [C₁-C₂₀ alkoxycarbonyl,] OH, C₁-C₂₀ alkoxy, halo or cyano, [.] X=NH, O, S, S=O, or SO₂.

28. (Amended) A compound of formula III.



wherein stereocenters * are R or S;


dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;

A and C are independently H, C₁–C₂₀ acylamino, C₁–C₂₀ acyloxy, C₁–C₂₀ linear or branched alkanoyl, C₁–C₂₀ alkoxycarbonyl, C₁–C₂₀ linear or branched alkoxy, C₁–C₂₀ linear or branched alkylamino, C₁–C₂₀ alkylcarboxylamino, C₁–C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; thiol, SOR or SOR₂; and f and are independently integers from 0 to 3;

B is independently H, C₁–C₂₀ acylamino, C₁–C₂₀ acyloxy, C₁–C₂₀ linear or branched alkanoyl, C₁–C₂₀ linear or branched alkenoyl, C₁–C₂₀ linear or branched alkenyl, C₁–C₂₀ alkoxycarbonyl, C₁–C₂₀ linear or branched alkoxy, C₁–C₂₀ linear or branched alkylamino, C₁–C₂₀ alkylcarboxylamino, C₁–C₂₀ carbalkoxy, C₅–C₂₀ aroyl, C₆–C₂₀ araalkanoyl, carboxyl, cyano, halo, hydroxy; and e is an integer from 1 to 3;

R', R'', and R''' are independently H or C₁–C₂₀ linear and branched alkyl or alkenyl groups which may contain substituents, COOH, C₁–C₂₀ alkoxycarbonyl, NH₂, CONH₂, C₁–C₂₀ acylamino, [C₁–C₂₀ alkoxycarbonyl,] OH, C₁–C₂₀ alkoxy, halo, cyano.

29. (Amended) A [pharmaceutically] pharmaceutical composition containing a blood glucose lowering effective amount of a compound of the formula III in a pharmaceutically acceptable carrier.



wherein stereocenters * are R or S;


dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;

A and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; thiol, SOR or SOR₂; and f and g are independently integers from 0 to 3;

B is independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ linear or branched alkenoyl, C₁-C₂₀ linear or branched alkenyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; C₅-C₂₀ aroyl, C₆-C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and e is an integer from 1 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear and branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxycarbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, [C₁-C₂₀ alkoxycarbonyl,] OH, C₁-C₂₀ alkoxy, halo, cyano.

30. (Amended) A method for lowering blood glucose in a subject comprising administering to said subject an effective blood glucose lowering amount of a composition of the formula III.



wherein stereocenters (designated by *) could be R- or S-.


dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;

A and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; thiol, SOR or SOR₂; and f and g are independently integers from 0 to 3;

B is independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ linear or branched alkenoyl, C₁-C₂₀ linear or branched alkenyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy, C₅-C₂₀ aroyl, C₆-C₂₀ araalkanoyl, carboxyl, cyano, halo, hydroxy; and e is an integer from 1 to 3;

R' , R'' , and R''' are independently H or C_1 - C_{20} linear and branched alkyl or alkenyl groups which may contain substituents, $COOH$, C_1 - C_{20} alkoxy, NH_2 , $CONH_2$, C_1 - C_{20} acylamino, $[C_1$ - C_{20} alkoxy,] OH , C_1 - C_{20} alkoxy, halo, cyano.

47. (Amended) A [pharmaceutically] pharmaceutical composition containing a serum triglyceride lowering effective amount of a compound of the formula II in a pharmaceutically acceptable carrier.



wherein stereocenters * are R or S;

dotted lines indicate[s] that a double bond may be present or absent, and the double bond geometry may be E or Z;


A , A' , and C are independently H, C_1 - C_{20} acylamino, C_1 - C_{20} acyloxy, C_1 - C_{20} alkoxy, C_1 - C_{20} linear or branched alkylamino, C_1 - C_{20} alkylcarboxylamino, C_1 - C_{20} carbalkoxy; carboxyl, cyano, halo, hydroxy; and t , u , and w are independently integers from 0 to 3;

B and B' are independently H, C_1 - C_{20} acylamino, C_1 - C_{20} acyloxy; C_1 - C_{20} alkanoyl, C_1 - C_{20} alkenoyl, C_1 - C_{20} alkenyl C_1 - C_{20} alkoxy, C_1 - C_{20} linear or branched alkoxy, C_1 - C_{20} linear or branched alkylamino, C_1 - C_{20} alkylcarboxylamino, C_1 - C_{20} carbalkoxy, C_6 - C_{20}

aroyl, C₆-C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and x and y are independently integers from 0 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxycarbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, [C₁-C₂₀ alkoxycarbonyl,] OH, C₁-C₂₀ alkoxy, halo or cyano. X = NH, O, S, S=O, or SO₂

48. (Amended) A method for lowering serum triglyceride in a subject comprising administering to said subject an effective serum triglyceride lowering amount of a composition of the formula II.




wherein stereocenters * R or S;

dotted lines indicates that a double bond may be present or absent, and the double bond geometry may be E or Z;

A, A', and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; and t, u, and w are independently integers from 0 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxy carbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, [C₁-C₂₀ alkoxy carbonyl], OH, C₁-C₂₀ alkoxy, halo or cyano.

49. (Amended) A pharmaceutically composition containing a serum triglyceride lowering effective amount of a compound of the formula III in a pharmaceutically acceptable carrier



30262456_1.DOC



dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;

A and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; thiol, SOR or SOR₂; and f and g are independently integers from 0 to 3;

B is independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ linear or branched alkenoyl, C₁-C₂₀ linear or branched alkenyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy, C₅-C₂₀ aroyl, C₆-C₂₀ araalkanoyl, carboxyl, cyano, halo, hydroxy; and e is an integer from 1 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear and branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxycarbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, [C₁-C₂₀ alkoxycarbonyl,] OH, C₁-C₂₀ alkoxy, halo or cyano.

50. (Amended) A method for lowering serum triglyceride in a subject comprising administering to said subject an effective serum triglyceride lowering amount of a composition of the formula III.




wherein stereocenters (designated by *) could be R- or S-.

dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;

A and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; thiol, SOR or SOR₂; and f and g are independently integers from 0 to 3;

B is independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ linear or branched alkenoyl, C₁-C₂₀ linear or branched alkenyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy, C₅-C₂₀ aroyl, C₆-C₂₀ araalkanoyl, carboxyl, cyano, halo, hydroxy; and e is an integer from 1 to 3;

67. (Amended) A [pharmaceutically] pharmaceutical composition containing a blood pressure lowering effective amount of a compound of the formula II in a pharmaceutically acceptable carrier.



dotted lines indicates that a double bond may be present or absent, and the double bond geometry may be E or Z;


B and B' are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ alkanoyl, C₁-C₂₀ alkenoyl, C₁-C₂₀ alkenyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy, C₆-C₂₀

aroyl, C₆-C₂₀ aralkenoyl, carboxyl, cyano, halo, hydroxy; and x and y are independently integers from 0 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxy, carbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, [C₁-C₂₀ alkoxy, carbonyl,] OH, C₁-C₂₀ alkoxy, halo or cyano.

X = NH, O, S, S=O, or SO₂

68. (Amended) A method for lowering blood pressure in a subject comprising administering to said subject an effective blood pressure lowering amount of a composition of the formula II.



wherein stereocenters * are R or S;

dotted lines indicates that a double bond may be present or absent, and the double bond geometry may be E or Z;


A, A', and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ alkoxy, C₁-C₂₀ alkoxy, carbonyl, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; and t, u, and w are independently integers from 0 to 3;

B and B' are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ alkanoyl, C₁-C₂₀ alkenoyl, C₁-C₂₀ alkenyl C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy, C₆-C₂₀ aroyl, C₆-C₂₀ araalkanoyl, carboxyl, cyano, halo, hydroxy; and x and y are independently integers from 0 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxycarbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, [C₁-C₂₀ alkoxycarbonyl,] OH, C₁-C₂₀ alkoxy, halo or cyano.

X = NH, O, S, S=O, or SO₂

69. (Amended) A [pharmaceutically] pharmaceutical composition containing a blood pressure lowering effective amount of a compound of the formula III in a pharmaceutically acceptable carrier.



wherein stereocenters (designated by *) could be R- or S-.



dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;

A and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; thiol, SOR or SOR₂; and f and g are independently integers from 0 to 3;

B is independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ linear or branched alkenoyl, C₁-C₂₀ linear or branched alkenyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy, C₅-C₂₀ aroyl, C₆-C₂₀ araalkanoyl, carboxyl, cyano, halo, hydroxy; and e is an integer from 1 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear and branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxycarbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, [C₁-C₂₀ alkoxycarbonyl,] OH, C₁-C₂₀ alkoxy, halo or cyano.

70. (Amended) A method for lowering blood pressure in a subject comprising administering to said subject an effective blood pressure lowering amount of a composition of the formula III



wherein stereocenters (designated by *) could be R- or S-.

dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;

A and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; thiol, SOR or SOR₂; and f and g are independently integers from 0 to 3;

B is independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ linear or branched alkenoyl, C₁-C₂₀ linear or branched alkenyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy, C₅-C₂₀ aroyl, C₆-C₂₀ aralkyl, carboxyl, cyano, halo, hydroxy; and e is an integer from 1 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxy carbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, [C₁-C₂₀ alkoxy carbonyl,] OH, C₁-C₂₀ alkoxy, halo or cyano.